8-K: INmune Bio Reports Q3 2025 Results, Advances Key Programs

INmune Bio Inc. announced its third quarter 2025 financial results, reporting a reduced net loss and significant progress across its CORDStrom, DN-TNF (XPro), and INKmune platforms.

Summary

• Net loss attributable to common stockholders for Q3 2025 was approximately $6.5 million, a significant reduction from $12.1 million in Q3 2024.
• Research and development expenses decreased to approximately $4.9 million in Q3 2025 from $10.1 million in Q3 2024.
• General and administrative expenses increased to approximately $2.5 million in Q3 2025 from $2.2 million in Q3 2024.
• Cash and cash equivalents stood at approximately $27.7 million as of September 30, 2025.
• The CORDStrom platform successfully completed its first two commercial pilot-scale manufacturing runs and is on target for MAA submission mid-2026, followed by a BLA filing.
• The DN-TNF (XPro) platform's Phase 2 MINDFuL trial in early Alzheimer's Disease with Inflammation (ADi) showed consistent clinical benefits, including slowed cognitive decline (effect size 0.27), reduced neuropsychiatric symptoms (effect size -0.23), and attenuated AD pathology biomarkers (pTau217 effect size -0.18).
• XPro1595 demonstrated an excellent safety profile with no reported cases of amyloid-related imaging abnormalities (ARIA), differentiating it from anti-amyloid therapies.
• The INKmune CARE-PC trial met its primary endpoint and two of three secondary endpoints, showing evidence of NK cell proliferation and generation of functional, memory-like NK cells.
• The INKmune CARE-PC trial was closed to further recruitment as enrolled patients had very high disease burden, beyond what would respond to immunotherapy, but provided sufficient data for future trial design.
• Key management changes include David Moss appointed President & CEO, Cory Ellspermann as CFO, and Kelly Ganjei as Chairman of the board.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for XPro1595 in Alzheimer's, including a favorable safety profile, which is a significant de-risking event. Financial results show a reduced net loss and R&D expenses. While the INKmune trial was adjusted, it still met primary endpoints and provided valuable data. Management changes also signal strategic evolution. The overall outlook for the pipeline is positive, despite ongoing cash burn and future funding needs.

Positives

• Net loss significantly reduced to approximately $6.5 million in Q3 2025 from $12.1 million in Q3 2024.
• Research and development expenses decreased by over 50% to approximately $4.9 million in Q3 2025 from $10.1 million in Q3 2024.
• CORDStrom platform achieved successful completion of first two commercial pilot-scale manufacturing runs, advancing towards regulatory filings.
• XPro1595 Phase 2 MINDFuL trial demonstrated consistent clinical benefits in early Alzheimer's Disease with Inflammation (ADi), including slowed cognitive decline (EMACC effect size 0.27) and reduced neuropsychiatric symptoms (NPI effect size -0.23).
• XPro1595 showed an excellent safety profile with no reported amyloid-related imaging abnormalities (ARIA), even in high-risk patients, differentiating it from other Alzheimer's therapies.
• INKmune CARE-PC trial met its primary endpoint and two of three secondary endpoints, demonstrating NK cell proliferation and generation of functional, memory-like NK cells.

Negatives

• General and administrative expenses increased to approximately $2.5 million in Q3 2025 from $2.2 million in Q3 2024.
• The INKmune CARE-PC trial was closed to further recruitment due to the high disease burden of enrolled patients, indicating a limitation in the current trial design for this patient population.
• The company continues to report a net loss, albeit reduced, indicating ongoing cash burn.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• Actual results and the timing of certain events and circumstances may differ materially from forward-looking statements due to various risks and uncertainties.
• The company's ability to produce more drug for clinical trials is a risk factor.
• The availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies, and future product commercialization is a significant risk.
• Risks and uncertainties relate to the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.
• There is no assurance that CORDstrom, XPro1595 (XPro, pegipanermin), and INKmune will be approved by the US Food and Drug Administration (FDA) or any regulatory body, or that any specific results will be achieved.

Future Outlook

The company anticipates filing an MAA submission for CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB) by mid-2026, followed shortly thereafter by an anticipated BLA filing with the FDA. An End of Phase 2 meeting with the FDA for XPro is expected in Q1 2026. Additional CORDStrom data and imaging data from the Phase 2 MINDFuL trial in Alzheimer's Disease are expected to be released in Q4 2025. Final data analysis for the INKmune CARE-PC trial is expected in Q4 2026.

Management Comments

• The company is on track to request an End of Phase 2 meeting with the FDA for XPro, anticipated to occur in Q1 2026.
• The INKmune CARE-PC trial has provided all the data needed to design a future randomized trial, leading to the closure of recruitment to ensure completion of follow-up by end of Q4 2025.

Industry Context

INmune Bio operates in the highly competitive and innovative fields of inflammation, immunology, and neurodegenerative diseases. The positive Phase 2 data for XPro1595 in Alzheimer's Disease with Inflammation (ADi), particularly its safety profile without ARIA, positions it as a potential differentiated therapy compared to existing anti-amyloid treatments that often carry ARIA risks. This could make XPro suitable for populations unable to take anti-amyloid therapies or as an adjunct. The CORDStrom platform's progress in RDEB addresses a rare disease with high unmet needs, while the INKmune platform aims to leverage the innate immune system for oncology, a rapidly evolving area. The company's focus on harnessing the innate immune system aligns with broader industry trends exploring novel immunomodulatory approaches beyond traditional targets.

Comparison to Industry Standards

• XPro1595's excellent safety profile with no reported cases of amyloid-related imaging abnormalities (ARIA) in its Phase 2 MINDFuL trial, especially with approximately 70% of participants at high risk for ARIA, significantly differentiates it from anti-amyloid therapies like aducanumab (Aduhelm) and lecanemab (Leqembi), which have shown ARIA as a common side effect. This suggests a potential advantage for patients susceptible to ARIA or as an adjunct therapy.
• The effect sizes observed for XPro1595 in cognitive decline (EMACC 0.27), neuropsychiatric symptoms (NPI -0.23), and pTau217 (-0.18) in the ADi population are comparable to or potentially favorable against some early-stage clinical data for other neuroinflammation-targeting drugs, though direct head-to-head comparisons are not provided in the filing.
• The CORDStrom platform's progress towards MAA and BLA submissions for recessive dystrophic epidermolysis bullosa (RDEB) places it among a limited number of advanced cell therapies targeting rare dermatologic conditions, where treatment options are scarce. Companies like Abeona Therapeutics (EB-101) and Krystal Biotech (Vyjuvek) are also active in gene/cell therapies for RDEB, setting a high bar for efficacy and safety.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from reduced net loss, strong clinical data for XPro, and pipeline advancements, potentially increasing investor confidence. Management changes could signal a new strategic direction.
• Patients: Potential for new therapeutic options, particularly for Alzheimer's Disease with XPro1595's promising safety and efficacy profile, and for recessive dystrophic epidermolysis bullosa with CORDStrom.
• Employees: Changes in key leadership roles (CEO, CFO, Chairman) may lead to shifts in corporate culture or strategic priorities.
• Regulatory Bodies: Upcoming MAA/BLA submissions for CORDStrom and an End of Phase 2 meeting for XPro indicate active engagement with regulatory pathways.

Next Steps

• Present additional CORDStrom data in Q4 2025.
• Release imaging data from the Phase 2 MINDFuL trial in Alzheimer's Disease in Q4 2025.
• Complete follow-up for the INKmune CARE-PC trial by the end of Q4 2025.
• Request an End of Phase 2 meeting with the FDA for XPro in Q1 2026.
• File an MAA submission for CORDStrom by mid-2026.
• File a BLA with the FDA for CORDStrom shortly after mid-2026.
• Release final data analysis for the INKmune CARE-PC trial in Q4 2026.

Key Dates

Recommendation

The filing presents compelling positive clinical data for XPro1595 in Alzheimer's Disease, particularly its excellent safety profile with no ARIA, which significantly de-risks the program and differentiates it from competitors. The substantial reduction in net loss and R&D expenses demonstrates improved financial management. While the INKmune trial saw an adjustment, it still yielded valuable data. The advancements in the CORDStrom platform also add to the long-term value proposition. For a clinical-stage biotechnology company, these positive developments, especially in a high-value indication like Alzheimer's, suggest strong potential for future growth and warrant a 'buy' recommendation for investors with a long-term horizon, despite the inherent risks of drug development and future funding needs.

Keywords

Biotechnology, Clinical-stage, Inflammation, Immunology, Alzheimer's Disease, Recessive Dystrophic Epidermolysis Bullosa, Oncology, Neuroinflammation, XPro1595, CORDStrom, INKmune, TNF inhibitor, Mesenchymal Stromal Cells, Natural Killer Cells, Rare Disease, Prostate Cancer